Company: PGEN
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001356090-25-000007
Chunk: 111

Company: PRECIGEN, INC.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 5
Chunk 111
---
 $91.06 $63.87 $186.13 S&P 500 Index100.00 80.00 95.96 104.09 116.26 Nasdaq Biotechnology Index100.00 89.59 113.40 112.40 125.60 

Company / Index3/31/20216/30/20219/30/202112/31/20213/31/20226/30/20229/30/202212/31/2022Precigen, Inc.$125.73 $118.98 $91.06 $67.70 $38.50 $24.45 $38.69 $27.74 S&P 500 Index122.97 133.02 133.33 147.52 140.23 117.17 110.98 118.84 Nasdaq Biotechnology Index124.70 135.90 134.20 124.80 110.00 99.00 99.50 111.20 

Company / Index3/31/20236/30/20239/30/202312/30/20233/31/20246/30/20249/29/202412/31/2024Precigen, Inc.$19.34 $20.99 $25.91 $24.45 $26.46 $28.83 $17.28 $20.44 S&P 500 Index127.19 137.75 132.72 147.64 162.63 169.01 178.36 182.05 Nasdaq Biotechnology Index108.90 107.60 104.40 115.40 116.90 120.00 125.90 113.80 

Recent Sales of Unregistered Securities and Use of Proceeds from Registered Securities

(a) Sales of Unregistered Securities

On December 27, 2024, we announced that we had entered into a Securities Purchase Agreement dated December 27, 2024 with investors, including Randal J. Kirk, our executive chairman of our board of directors, affiliates of Patient Capital 

Table of Contents 

Management and Bill Miller, as well as certain other investors for the sale of our 8.00% Series A Convertible Perpetual Preferred Stock (the "Series A Preferred Stock